Dr. Wenseng “Wendy” Pan, leader of Goodwin’s Life Sciences practice in Asia, specializes in mergers and acquisitions, technology-based transactions, licensing and strategic partnerships as well as financing transactions (including both venture/private equity financings and IPOs), especially in the life sciences and technology industries and in cross-border settings.

Dr. Pan has advised private equity firms in leveraged buy-outs and has represented financial institutions, technology, media and telecoms (TMT), biopharmaceutical, manufacturing, publishing, electronics companies and retail chains in stock and/or cash acquisitions, mergers, tender offers and going-private transactions. She has advised on mergers and acquisitions transactions with an aggregate value of more than US $10 billion. She also advises on company formation, corporate governance, private and public financings. Dr. Pan has also advised life sciences companies and technology companies in structuring and negotiating complex strategic transactions and other commercial arrangements.

Her practice covers product and technology licensing, strategic partnerships and joint venture formations and research, product development and commercialization collaborations as well as mergers and acquisitions and private investments. She has deep experiences in representing licensors as well as licensees, involving a broad spectrum of technologies. As a former scientist and a registered U.S. patent attorney, she possesses a unique set of skills for counseling her clients on intellectual property-related issues.

Dr. Pan is ranked for excellence by the 2023 edition of Chambers Greater China Region. Dr. Pan advised Sichuan Kelun-Biotech Biopharmaceutical on its $9.5 billion exclusive license and collaboration agreement with Merck to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer, which won Impact Deal of the Year at the LMG Life Sciences Americas Awards 2023.